The Institute for Clinical and Economic Review on Friday released a report outlining a planned review of Duchenne muscular dystrophy treatments.
ICER plans to review Sarepta Therapeutics’ eteplirsen and golodirsen, and PTC Therapeutics’ deflazacort. While the Food and Drug Administration has already signed off on eteplirsen and deflazacort, the agency is expected to make a decision on golodirsen this year.
The report will be discussed during the July meeting of the New England Comparative Effectiveness Public Advisory Council.
Stakeholders can submit comments and make suggestions on the scope of the report until the input period ends 5 p.m. EST Feb. 1.
Click here to read the full press release on ICER’s website.
To read the draft scoping document outlining the planned review, click here.
